IOVAIovance Biotherapeutics, Inc.
Price
+613%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growing in the filings, the market undecided.
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. TIL cell therapies harness the individual immune system’s ability to recognize and destroy diverse cancer cells that are unique to each patient.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $99M in Q2 2026 (quarter ended Jun 30, 2026), up 66% from the same quarter a year earlier. That came with a gross margin of 56% and net loss of $47M. For the full year FY2025, revenue was $264M (+61% year on year) and net income −$391M. Its largest product in Q2 2026 was Amtagvi at $91M, 91% of the disclosed total, well ahead of Proleukin at 8.7%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026On October 5, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
- Sep 29, 2026On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance.Other event · Form 8-K
- Aug 6, 2026On August 6, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $99.3MThe company’s own SEC segment disclosure.
- Amtagvi$90.7M91%
- Proleukin$8.6M9%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.